Femoxetine

Femoxetine

Femoxetine is a serotonin reuptake inhibitor (SRI) that was developed by Pfizer in the 1970s for the treatment of depression. Despite showing promise in clinical trials, it was never marketed.

History

Femoxetine was first synthesized by Pfizer in the 1970s as part of a research program aimed at developing new antidepressant medications. Early clinical trials suggested that it was effective in treating depression, but further development was halted for unknown reasons.

Pharmacology

As a serotonin reuptake inhibitor, femoxetine works by increasing the levels of serotonin in the brain. Serotonin is a neurotransmitter that is involved in regulating mood, and increasing its levels can help to alleviate the symptoms of depression.

Clinical Trials

In the clinical trials that were conducted, femoxetine was found to be effective in treating depression. However, the trials were small and further research is needed to confirm these findings.

Current Status

Despite the promising results from the clinical trials, femoxetine was never marketed. The reasons for this are not clear, but it may be due to the development of other, more effective antidepressants.

See Also

• Serotonin reuptake inhibitor
• Pfizer
• Depression

‎